Antihypertensive and antihyperglycemic effects of combinations of losartan with metformin and/or glibenclamide in desoxycorticosterone acetate and streptozotocin-induced hypertensive diabetic rats

Table 5 Effects of losartan, metformin and glibenclamide on diastolic blood pressure of DOCA + STZ hypertensive diabetic rats

Treatment	Initial (mmHg)	Week 1	Week 2	Week 3	Week 4	Week 8
Normal Control	66.00 ± 0.00	59.67 ± 3.18	70.00 ± 8.62	75.00 ± 8.50	70.67 ± 4.33	80.00 ± 7.37
HD Control	64.00 ± 1.00	85.33 ± 3.71^*	94.33 ± 0.67^*	100.00 ± 1.00	106.00 ± 4.51^*	80.33 ± 2.91
HD + LOS + MET	77.67 ± 3.76	79.33 ± 7.69	85.00 ± 1.53	87.67 ± 11.78	66.00 ± 1.15^#	88.00 ± 6.25
HD + LOS + GLB	79.33 ± 3.71	74.33 ± 6.33	76.33 ± 0.67	69.67 ± 3.18	68.00 ± 7.02^#	79.00 ± 0.00
HD + LOS + MET + GLB	78.67 ± 8.67	75.33 ± 5.33	72.67 ± 3.71^#	77.33 ± 7.33	66.67 ± 6.67^#	90.33 ± 2.33

All values are expressed as mean ± SEM (n = 5). *P < 0.05 when compared with normal control; ^#P < 0.05 when compared with hypertensive diabetic control. (HD Control Hypertensive Diabetic Control, HD Hypertensive Diabetic Rats, LOS Losartan, MET Metformin, GLB Glibenclamide)

ISSN: 2233-7660